Lust, H., Schultz, L. M., Kwon, S., Roloff, G. W., Aldoss, I., Baggott, C., John, S., Rossoff, J., McNerney, K. O., Fabrizio, V. A., Talano, J.-A., Moskop, A., Curran, K. J., Phillips, C. L., Karras, N. A., Baumeister, S. H. C., Cooper, S., Hermiston, M. L., Satwani, P., … Faramand, R. G. (2025). Real World Outcomes for Young Adult Patients Receiving CD19 CAR T-cell Therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014846

Banerjee, R., Richards, A., Midha, S., Afrough, A., Anwer, F., Atanackovic, D., Atrash, S., Bachanova, V., Beitinjaneh, A. M., Ouchveridze, E., Castaneda Puglianini, O., Chhabra, S., Cicero, K. I., Davis, J. A., Dhakal, B., Dima, D., Ferreri, C. J., Forsberg, P. A., Freeman, C. L., … Kaur, G. (2025). Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016131

Naggayi, S. K., Kalibbala, D., Mboizi, V., Ssenkusu, J. M., Jin, Z., Rosano, C., Munube, D., Wambaka, B., Namazzi, R., Kasirye, P. G., Kabatabaazi, M., Nambatya, G., Murungi, S., Nabaggala, C., Nakafeero, M. R., Troidl, I. R., Opoka, R. O., Idro, R., Bangirana, P., & Green, N. S. (2025). Neurocognitive Gains Among Ugandan Children with Sickle Cell Anemia on Hydroxyurea: 18-month trial interim results. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015073

Song, A., Mellgard, G., Bellofiore, C., Basset, M., Nuvolone, M., Foli, A., Merlini, G., Maurer, M. S., Mapara, M. Y., Bhutani, D., Lentzsch, S., Shaish, H., Palladini, G., Chakraborty, R., & Milani, P. (2025). Diffuse Lung Involvement as a Rare Presentation of Systemic AL Amyloidosis: A Retrospective Cohort Study. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015646

Shaw, R., Yoon, J. J., Johnston, H., Davidson, M. B., Siddon, A. J., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Kassner, J., Rampal, R. K., Guru Murthy, G. S., Bradley, T. J., Abaza, Y., Garcia, J. S., Gupta, V., … Patel, A. A. (2025). Assessing AML-based risk criteria in patients with accelerated/blast-phase MPN treated with less-intensive therapy. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015712

Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D., Hosszu, K., Cancio, M. I., Jakubowski, A. A., Scaradavou, A., Boelens, J. J., Sauter, C. S., Perales, M.-A., Giralt, S. A., Taylor, C., Chaudhari, J., Wang, X., Rivière, I., … Curran, K. J. (2025). Allogeneic Off-the-Shelf CAR T-Cell Therapy for Relapsed or Refractory B-Cell Malignancies. Blood Advances. https://doi.org/10.1182/bloodadvances.2024015157

Brown, J. R., Li, J., Eichhorst, B., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Huang, R., Shi, Y., Idoine, A., Salmi, T., Cohen, A. C., & Shadman, M. (2025). ACQUIRED MUTATIONS IN PATIENTS WITH RELAPSED/REFRACTORY CLL WHO PROGRESSED IN THE ALPINE STUDY. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014206

Marks, L. J., Ritter, V., Agrusa, J., Kamdar, K. Y., Rivers, J., Gardner, R. A., Ehrhardt, M. J., Devine, K. J., Phillips, C. A., Reilly, A. F., August, K., Weinstein, J. L., Satwani, P., Forlenza, C. J., Smith, C. M., Greer, C., Afify, Z., Lin, C. H., Belsky, J. A., … Aftandilian, C. (2025). Pediatric relapsed/refractory ALK+ anaplastic large cell lymphoma treatment and outcomes in the targeted drug era. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014745

O’Farrell, C., Grimes, A. B., Nakano, T. A., Klaassen, R. J., Lambert, M. P., Neunert, C. E., Rothman, J. A., Shimano, K. A., & Grace, R. F. (2025). International Consensus in Aiming to Define “Refractory ITP.” Blood Advances. https://doi.org/10.1182/bloodadvances.2024015219

Soumerai, J. D., Barrientos, J. C., Ahn, I. E., Coombs, C. C., Gladstone, D. E., Hoffmann, M. S., Kittai, A. S., Jacobs, R. W., Lipsky, A., Patel, K., Rhodes, J. M., Skarbnik, A. P., Thompson, M. C., Ermann, D. A., Reville, P. K., Shah, H. R., Brown, J. R., & Stephens, D. M. (2024). Consensus Recommendations from the 2024 Lymphoma Research Foundation Workshop on Treatment Selection and Sequencing in CLL or SLL. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014474

Han, J. X., Koh, M. J., Boussi, L., Sorial, M., McCabe, S. M., Peng, L., Singh, S., Eche-Ugwu, I. J., Gabler, J., Fernandez Turizo, M. J., MacVicar, C. T., Garg, A. R., Disciullo, A., Chopra, K., Lenart, A. W., Nwodo, E., Barnes, J. A., Koh, M. J., Miranda, E. C. M., … Jain, S. (2024). Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014674

Maese, L. D., Loh, M. L., Choi, M. R., Agarwal, S., Aoki, E., Liang, Y., Lin, T., Girgis, S., Chen, C., Roller, S. G., Chandrasekaran, V., Iannone, R., Silverman, L. B., Raetz, E. A., & Rau, R. E. (2024). Recombinant Erwinia Asparaginase (JZP458) in ALL/LBL: Complete Follow-Up of the Children’s Oncology Group AALL1931 Study. Blood Advances. https://doi.org/10.1182/bloodadvances.2024013346

Siegal, D. M., Tseng, E. K., Schünemann, H. J., Angchaisuksiri, P., Cuker, A., Dane, K. E., DeSancho, M. T., Diuguid, D. L., Griffin, D. O., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K., Terrell, D. R., Akl, E. A., Al Jabiri, R. N., Al Jabiri, Y. N., … Nieuwlaat, R. (2024). ASH living guidelines on use of anticoagulation for thromboprophylaxis in patients with COVID-19: executive summary. Blood Advances. https://doi.org/10.1182/bloodadvances.2024014219

Kim, T. O., Geris, J. M., Flanagan, J. M., Grace, R. F., Lambert, M. P., O’Farrell, C., Rose, M. J., Shimano, K. A., Niss, O., Neunert, C., Nakano, T. A., MacMath, D., Dinu, B., Kirk, S. E., Neufeld, E. J., Despotovic, J. M., Scheurer, M. E., & Grimes, A. B. (2024). Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia. Blood Advances, 8(21), 5529–5538. https://doi.org/10.1182/bloodadvances.2024012776

Mejia Saldarriaga, M., Pan, D., Unkenholz, C., Mouhieddine, T. H., Velez-Hernandez, J. E., Engles, K., Fein, J. A., Monge, J., Rosenbaum, C., Pearse, R., Jayabalan, D., Gordillo, C., Chan, H. T., Yamshon, S., Thibaud, S., Mapara, M., Inghirami, G., Lentzsch, S., Reshef, R., … Bustoros, M. (2024). Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Advances, 8(15), 3859–3869. https://doi.org/10.1182/bloodadvances.2023012470

Nakano, T. A., Grimes, A. B., Klaassen, R. J., Lambert, M. P., Neunert, C. E., Rothman, J. A., Shimano, K. A., Amend, C., Askew, M., Badawy, S. M., Baker, J. M., Breakey, V., Crary, S. E., Davini, M., Fritch Lilla, S., Gilbert, M., Hays, T., Hege, K., Hillier, K., … Grace, R. F. (2024). What’s in a name: defining pediatric refractory ITP. Blood Advances. https://doi.org/10.1182/bloodadvances.2024012707

Mei, Z., Addo, O. Y., Jefferds, M. E. D., Flores-Ayala, R. C., & Brittenham, G. M. (2024). Physiologically based trimester-specific serum ferritin thresholds for iron deficiency in US pregnant women. Blood Advances, 8(14), 3745–3753. https://doi.org/10.1182/bloodadvances.2024013460

Neunert, C. E., Arnold, D. M., Grace, R. F., Kuhne, T., McCrae, K. R., & Terrell, D. R. (2024). The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. Blood Advances, 8(13), 3578–3582. https://doi.org/10.1182/bloodadvances.2023012541

Ramachandran, R., Shah, D., Luo, C., Shah, V., Cliff, E. R. S., Sanchorawala, V., Lentzsch, S., & Chakraborty, R. (2024). The clinical trials landscape in immunoglobulin light chain amyloidosis: a systematic review. Blood Advances, 8(13), 3464–3467. https://doi.org/10.1182/bloodadvances.2024012737

DeFilipp, Z., Kim, H. T., Spyrou, N., Katsivelos, N., Kowalyk, S., Eng, G., Kasikis, S., Beheshti, R., Baez, J., Akahoshi, Y., Ayuk, F., Choe, H., Etra, A., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Qayed, M., Reshef, R., … Chen, Y.-B. (2024). The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD. Blood Advances, 8(13), 3488–3496. https://doi.org/10.1182/bloodadvances.2024012561

Patel, A. A., Yoon, J. J., Johnston, H., Davidson, M. B., Shallis, R. M., Chen, E. C., Burkart, M., Oh, T. S., Iyer, S. G., Madarang, E., Muthiah, C., Gross, I., Dean, R., Kassner, J., Viswabandya, A., Madero-Marroquin, R., Rampal, R. K., Guru Murthy, G. S., Bradley, T., … Odenike, O. (2024). Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era. Blood Advances, 8(13), 3468–3477. https://doi.org/10.1182/bloodadvances.2024012880

Etra, A., El Jurdi, N., Katsivelos, N., Kwon, D., Gergoudis, S., Morales, G., Spyrou, N., Kowalyk, S., Aguayo-Hiraldo, P., Akahoshi, Y., Ayuk, F., Baez, J., Betts, B. C., Chanswangphuwana, C., Chen, Y.-B., Choe, H., DeFilipp, Z., Gleich, S., Hexner, E., … Holtan, S. (2024). Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD. Blood Advances, 8(12), 3284–3292. https://doi.org/10.1182/bloodadvances.2023011049

Lu, Z., Wang, Y., Assumpção, A. L. F. V., Liu, P., Kopp, A., Saka, S., Mcilwain, S. J., Viny, A. D., Brand, M., & Pan, X. (2024). Yin Yang 1 regulates cohesin complex protein SMC3 in mouse hematopoietic stem cells. Blood Advances, 8(12), 3076–3091. https://doi.org/10.1182/bloodadvances.2023011411

Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Akahoshi, Y., Spyrou, N., Hoepting, M., Aguayo-Hiraldo, P., Ayuk, F., Chanswangphuwana, C., Choe, H. K., Eder, M., Etra, A. M., Grupp, S. A., Hexner, E. O., Hogan, W. J., Kitko, C. L., Kraus, S., Al Malki, M. M., Merli, P., Qayed, M., Reshef, R., Schechter, T., … Nakamura, R. (2024). Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood Advances, 8(8), 2047–2057. https://doi.org/10.1182/bloodadvances.2023012091

Paudel, B. B., Tan, S.-F., Fox, T. E., Ung, J., Golla, U., Shaw, J. J. P., Dunton, W., Lee, I., Fares, W. A., Patel, S., Sharma, A., Viny, A. D., Barth, B. M., Tallman, M. S., Cabot, M., Garrett-Bakelman, F. E., Levine, R. L., Kester, M., Feith, D. J., … Loughran, T. P. (2024). Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes. Blood Advances, 8(5), 1137–1142. https://doi.org/10.1182/bloodadvances.2023010535

Hijiya, N., Maschan, A., Rizzari, C., Shimada, H., Dufour, C., Goto, H., Kang, H. J., Guinipero, T., Karakas, Z., Bautista, F., Ducassou, S., Yoo, K. H., Zwaan, C. M., Millot, F., Patterson, B. C., Samis, J., Izquierdo, M., Titorenko, K., Li, S., & Sosothikul, D. (2023). The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study. Blood Advances, 7(23), 7279–7289. https://doi.org/10.1182/bloodadvances.2023010122

Ruan, J., Zain, J., Palmer, B., Jovanovic, B., Mi, X., Swaroop, A., Winter, J. N., Gordon, L. I., Karmali, R., Moreira, J., Petrich, A. M., & Pro, B. (2023). Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Advances, 7(19), 5771–5779. https://doi.org/10.1182/bloodadvances.2023009767

Al Malki, M. M., London, K., Baez, J., Akahoshi, Y., Hogan, W. J., Etra, A., Choe, H., Hexner, E., Langston, A., Abhyankar, S., Ponce, D. M., DeFilipp, Z., Kitko, C. L., Adekola, K., Reshef, R., Ayuk, F., Capellini, A., Chanswangphuwana, C., Eder, M., … Levine, J. E. (2023). Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Advances, 7(17), 5189–5198. https://doi.org/10.1182/bloodadvances.2023009853

Spyrou, N., Akahoshi, Y., Ayuk, F., Holler, E., Choe, H., Etra, A., Hogan, W. J., Rösler, W., Hexner, E., DeFilipp, Z., Reshef, R., Chanswangphuwana, C., Qayed, M., Kraus, S., Eder, M., Javorniczky, N. R., Grupp, S. A., Kitko, C. L., Merli, P., … Ferrara, J. L. M. (2023). The utility of biomarkers in acute GVHD prognostication. Blood Advances, 7(17), 5152–5155. https://doi.org/10.1182/bloodadvances.2023009929

Lee, T. D., Aisner, D. L., David, M. P., Eno, C. C., Gagan, J., Gocke, C. D., Guseva, N. V., Haley, L., Jajosky, A. N., Jones, D., Mansukhani, M. M., Mroz, P., Murray, S. S., Newsom, K. J., Paulson, V., Roy, S., Rushton, C., Segal, J. P., Senaratne, T. N., … Kim, A. S. (2023). Current clinical practices and challenges in molecular testing: a GOAL Consortium Hematopathology Working Group report. Blood Advances, 7(16), 4599–4607. https://doi.org/10.1182/bloodadvances.2023010149

Akahoshi, Y., Spyrou, N., Hogan, W. J., Ayuk, F., DeFilipp, Z., Weber, D., Choe, H. K., Hexner, E. O., Rösler, W., Etra, A. M., Sandhu, K., Yanik, G. A., Chanswangphuwana, C., Kitko, C. L., Reshef, R., Kraus, S., Wölfl, M., Eder, M., Bertrand, H., … Chen, Y.-B. (2023). Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD. Blood Advances, 7(16), 4479–4491. https://doi.org/10.1182/bloodadvances.2023009885

Levy, B., Baughn, L. B., Akkari, Y., Chartrand, S., LaBarge, B., Claxton, D., Lennon, P. A., Cujar, C., Kolhe, R., Kroeger, K., Pitel, B., Sahajpal, N., Sathanoori, M., Vlad, G., Zhang, L., Fang, M., Kanagal-Shamanna, R., & Broach, J. R. (2023). Optical genome mapping in acute myeloid leukemia: a multicenter evaluation. Blood Advances, 7(7), 1297–1307. https://doi.org/10.1182/bloodadvances.2022007583

Brownlie, R. J., Kennedy, R., Wilson, E. B., Milanovic, M., Taylor, C. F., Wang, D., Davies, J. R., Owston, H., Adams, E. J., Stephenson, S., Caeser, R., Gewurz, B. E., Giannoudis, P. V., Scuoppo, C., McGonagle, D., Hodson, D. J., Tooze, R. M., Doody, G. M., Cook, G., … Klein, U. (2023). Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma. Blood Advances, 7(15), 3874–3890. https://doi.org/10.1182/bloodadvances.2022009044

Chakraborty, R., Al Hadidi, S., Scheffer Cliff, E. R., & Mohyuddin, G. R. (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Advances, 7(15), 3932–3935. https://doi.org/10.1182/bloodadvances.2023009658

de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan, M., Blum, W., Cilloni, D., Hiwase, D. K., … Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117–3127. https://doi.org/10.1182/bloodadvances.2022009411

Gladstone, D. E., D’Alessio, F., Howard, C., Lyu, M.-A., Mock, J. R., Gibbs, K. W., Abrams, D., Huang, M., Zeng, K., Herlihy, J. P., Castillo, S. T., Bassett, R., Sadeghi, T., Parmar, S., Flowers, C. R., Mukherjee, S., Schoenfeld, D., Thall, P. F., & Slutsky, A. S. (2023). Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS. Blood Advances, 7(13), 3075–3079. https://doi.org/10.1182/bloodadvances.2022009619

Li, S., Fu, J., Walker, C. J., Yang, J., Bhutani, D., Chakraborty, R., Mamillapalli, N., Mapara, M. Y., Landesman, Y., & Lentzsch, S. (2023). Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects. Blood Advances, 7(12), 2926–2937. https://doi.org/10.1182/bloodadvances.2021006638

McNerney, K. O., Si Lim, S. J., Ishikawa, K., Dreyzin, A., Vatsayan, A., Chen, J. J., Baggott, C., Prabhu, S., Pacenta, H. L., Philips, C., Rossoff, J., Stefanski, H. E., Talano, J.-A., Moskop, A., Verneris, M., Myers, D., Karras, N. A., Brown, P., Bonifant, C. L., … Schultz, L. M. (2023). HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Advances, 7(12), 2758–2771. https://doi.org/10.1182/bloodadvances.2022008893

Allen, P. B., Lu, X., Chen, Q., O’Shea, K., Chmiel, J. S., Slonim, L. B., Sukhanova, M., Savas, H., Evens, A. M., Advani, R., Pro, B., Karmali, R., Palmer, B., Bayer, R. A., Eisner, R. M., Mou, E., Dillehay, G., Gordon, L. I., & Winter, J. N. (2023). Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Advances, 7(12), 2670–2676. https://doi.org/10.1182/bloodadvances.2022008116

Kinoshita, H., Mandava, M., Jensen-Wachspress, M., Lang, H., Joy, E., Tanna, J., McCann, C. D., O’Brien, S., Burnett, S., Shibli, A., Hoq, F., Bhatia, M., Hanley, P. J., Dávila Saldaña, B., Mahadeo, K. M., Bollard, C. M., Keller, M. D., & Abraham, A. (2023). Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease. Blood Advances, 7(10), 2105–2116. https://doi.org/10.1182/bloodadvances.2022008219

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Li, Y., Xu-Monette, Z. Y., Abramson, J., Sohani, A. R., Bhagat, G., Tzankov, A., Visco, C., Zhang, S., Dybkaer, K., Pan, Z., Xu, M., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Go, H., van Krieken, J. H., Winter, J. N., Ponzoni, M., … Young, K. H. (2023). EBV-positive DLBCL frequently harbors somatic mutations associated with clonal hematopoiesis of indeterminate potential. Blood Advances, 7(7), 1308–1311. https://doi.org/10.1182/bloodadvances.2022008550

Fraga de Andrade, I., Johnson, K. D., Mehta, C., Dewey, C. N., Basu, U., & Bresnick, E. H. (2023). RNA-regulatory exosome complex suppresses an apoptotic program to confer erythroid progenitor cell survival in vivo. Blood Advances, 7(4), 586–601. https://doi.org/10.1182/bloodadvances.2022008481

Stefanski, H. E., Eaton, A., Baggott, C., Rossoff, J., Verneris, M. R., Prabhu, S., Pacenta, H. L., Phillips, C. L., Talano, J.-A., Moskop, A., Margossian, S. P., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, M. C., Keating, A. K., … Schultz, L. M. (2023). Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Advances, 7(4), 541–548. https://doi.org/10.1182/bloodadvances.2022007246

Green, N. S., Zapfel, A., Nnodu, O. E., Franklin, P., Tubman, V. N., Chirande, L., Kiyaga, C., Chunda-Liyoka, C., Awuonda, B., Ohene-Frempong, K., Inusa, B. P. D., Ware, R. E., Odame, I., Ambrose, E. E., Dogara, L. G., Oron, A. P., Willett, C., Thompson, A. A., Berliner, N., … Novelli, E. M. (2022). The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances, 6(24), 6187–6197. https://doi.org/10.1182/bloodadvances.2022007698

Mishkin, A. D., Cheung, S. G., Hoffman, A., Leimbach, E. J., Dosovitz, S., & Mapara, M. (2022). High incidence of suicidal ideation in a series of patients with sickle cell disease after hematopoietic stem cell transplantation. Blood Advances, 6(19), 5542–5545. https://doi.org/10.1182/bloodadvances.2021006752

Savage, K. J., Horwitz, S. M., Advani, R., Christensen, J. H., Domingo-Domenech, E., Rossi, G., Morschhauser, F., Alpdogan, O., Suh, C., Tobinai, K., Shustov, A., Trneny, M., Yuen, S., Zinzani, P. L., Trümper, L., Ilidge, T., O’Connor, O. A., Pro, B., Miao, H., … Iyer, S. (2022). Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Advances, 6(19), 5550–5555. https://doi.org/10.1182/bloodadvances.2020003971

Cuker, A., Tseng, E. K., Schünemann, H. J., Angchaisuksiri, P., Blair, C., Dane, K., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D. M., Skara, M., Terrell, D. R., … Nieuwlaat, R. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 6(17), 4975–4982. https://doi.org/10.1182/bloodadvances.2022007940